Coya Therapeutics (COYA) Net Income (2022 - 2026)
Coya Therapeutics (COYA) posted Net Income of -$7.2 million for Q1 2026, up 15.88% sequentially from -$8.6 million in Q4 2025, and up 1.37% YoY from -$7.1 million in Q1 2025.
Coya Therapeutics (COYA) Net Income (2022 - 2026) Analysis & Trends
Coya Therapeutics has reported Net Income for 5 years, with the latest figure at -$7.2 million in Q1 2026.
- Quarterly Net Income rose 1.37% year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.7 million (up 13.13% YoY) and the FY2025 annual result came in at -$21.3 million, down 42.98% from the prior year.
- Net Income climbed to -$7.2 million in Q1 2026 per COYA's latest filing, from -$8.6 million in the prior quarter.
- Over five years, Net Income peaked at -$1.7 million in Q1 2022 and troughed at -$12.2 million in Q4 2024.
- A 5-year average of -$5.3 million and a median of -$4.5 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2024 and 2025: Net Income tumbled 220.46% in 2024, then surged 41.88% in 2025.
- Over 5 years, Net Income stood at -$3.0 million in 2022, then dropped by 26.85% to -$3.8 million in 2023, then sank by 220.46% to -$12.2 million in 2024, then gained by 29.82% to -$8.6 million in 2025, then increased by 15.88% to -$7.2 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$7.2 million, -$8.6 million, and -$4.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - | -6.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.64 Mn |
| Mar 31, 2026 | -7.21 Mn |
| Dec 31, 2025 | -8.57 Mn |
| Sep 30, 2025 | -4.86 Mn |
| Jun 30, 2025 | -6.09 Mn |
| Mar 31, 2025 | -7.31 Mn |
| Dec 31, 2024 | -12.21 Mn |
| Sep 30, 2024 | -8.36 Mn |
| Jun 30, 2024 | -2.89 Mn |
| Mar 31, 2024 | -5.05 Mn |
| Dec 31, 2023 | -3.81 Mn |
| Sep 30, 2023 | -4.53 Mn |
| Jun 30, 2023 | -4.44 Mn |
| Mar 31, 2023 | -3.98 Mn |
| Dec 31, 2022 | -3.00 Mn |
| Sep 30, 2022 | -2.66 Mn |
| Jun 30, 2022 | -3.45 Mn |
| Mar 31, 2022 | -1.70 Mn |